{"id":4036,"date":"2026-11-02T09:00:00","date_gmt":"2026-11-02T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4036"},"modified":"2026-11-02T23:23:19","modified_gmt":"2026-11-03T03:23:19","slug":"specific-biologics-closes-35-million-dollar-series-a","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4036","title":{"rendered":"Specific Biologics Closes 35 Million Dollar Series A"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Specific Biologics<\/p>\n

Event Type<\/strong><\/p>\n

Series A financing<\/p>\n

Modality<\/strong><\/p>\n

Dualase nuclease genome editing (repeat excision)<\/p>\n

Asset<\/strong><\/p>\n

C9ORF72 repeat-expansion editing candidate<\/p>\n

Target<\/strong><\/p>\n

C9ORF72 repeat expansion<\/p>\n

Disease Area<\/strong><\/p>\n

Amyotrophic lateral sclerosis<\/p>\n

Summary<\/h4>\n

Specific Biologics announced November 2 the close of an oversubscribed US$35 million Series A led by Hatteras Venture Partners. It plans to fund its C9ORF72 repeat-expansion editing candidate through initial biomarker proof of concept in the first cohort of an adaptive Phase I\/II ALS study.<\/p>\n

Existing investors Lumira Ventures and adMare BioInnovations joined new participants Genesys Capital, BDC Life Sciences Venture Fund, DeepWork Capital, and Seido Capital. The company described the round as closed, while it did not disclose a runway or clinical-start date in the announcement.<\/p>\n

Deep Analysis<\/h4>\n

The platform seeks to excise a pathogenic repeat expansion rather than suppress its RNA products transiently. Inference 1:<\/strong> financing can advance a differentiated, potentially durable ALS approach to human biomarker evidence; support comes from the disclosed round and indication-specific plan, while delivery to disease-relevant cells and on-target editing remain unverified in people. Inference 2:<\/strong> the investment may primarily buy de-risking time for a technically difficult editing modality; preclinical claims and lack of human efficacy data support this, while a clear genetic target and defined biomarker path argue for tractable early testing. Edit efficiency, CNS distribution, off-target and structural-variant assays, durability, immune response, manufacturing yield, and trial registry details are needed to upgrade the thesis.<\/p>\n

Company and Product Background<\/h4>\n

C9ORF72 repeat expansions are a genetic cause of ALS. Specific\u2019s Dualase nuclease platform is designed to remove expanded DNA repeats; clinical translation requires safe delivery to relevant nervous-system cells and durable correction without harmful cuts.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • This is newly closed private capital, not an option value or future tranche.<\/li>\n
  • The lead asset remains preclinical or clinical-entry stage based on this release; a trial start is not established.<\/li>\n
  • Lead investor and use of proceeds are named; runway and detailed terms are undisclosed.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    The financing is strategically notable because it funds a direct genome-editing test in repeat-expansion ALS. It does not validate safety, delivery, or clinical efficacy. The first human molecular biomarker and dose-escalation data are the key discriminators.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 3 of 5. Signal Direction: positive for financing; therapeutic direction uncertain. Confidence in Facts: high for round announcement, moderate for company-reported program maturity. Confidence in Interpretation: low to moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Specific Biologics announced November 2 the close of an oversubscribed US$35 million Series A led by Hatteras Venture Partners. It plans to fund its C9ORF72 repeat-expansion editing candidate through initial biomarker proof of concept…<\/p>\n","protected":false},"author":1,"featured_media":4040,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[792,1330,369,879,1329],"class_list":["post-4036","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-deals-and-financing","tag-als","tag-c9orf72","tag-gene-editing","tag-series-a","tag-specific-biologics"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4036","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4036"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4036\/revisions"}],"predecessor-version":[{"id":4044,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4036\/revisions\/4044"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4040"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4036"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4036"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4036"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}